PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study

Summary

This is a prospective, single-arm, open-label feasibility trial conducted at the MD Anderson Sarcoma Center and Cardio-Oncology Clinic. The study will enroll young adults (18-39 years) with soft tissue or bone sarcoma who are overweight (BMI 25-29.9 kg/m² with ≥1 cardiovascular risk factor) or obese (BMI ≥30 kg/m²), have completed Dox-based chemotherapy (≥300 mg/m²) approximately three months prior to enrollment, and have preserved LVEF (≥50%) preenrollment.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Sarcoma,Soft Tissue

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 to 39 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

M.D. Anderson Cancer Center

Last updated on ClinicalTrials.gov

October 20, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites